SynthesisStem cell research & therapy2025
Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.
Synthesis in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Safety, feasibility, and exploratory biomarker findings of bone marrow-derived mesenchymal stromal cells in hospitalized severe COVID-19: a phase I/II randomized trial.Journal of thoracic disease · 2026Article
- Review
- The gut-lung axis in ARDS: beyond microbial translocation.Respiratory research · 2026Review
- Factors Associated with Live Birth After Placenta-Derived Mesenchymal Stromal Cell Therapy in Women with Recurrent Intrauterine Adhesions and Thin Endometrium.Life (Basel, Switzerland) · 2026Article
- One syndrome, many diseases: toward precision pharmacotherapy in acute respiratory distress syndrome.Frontiers in pharmacology · 2026Review
- Beyond immunomodulation: mechanisms and synergistic strategies of mesenchymal stem cells in promoting alveolar epithelial and endothelial repair in ARDS.Frontiers in immunology · 2026Review
- Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease.Extracellular vesicles and circulating nucleic acids · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough numerous clinical trials have explored stem cell-based therapies for acute respiratory distress syndrome (ARDS), their findings are inconsistent. This meta-analysis aimed to comprehensively evaluate the efficacy and safety of stem cell-based therapies, including mesenchymal stem/stromal cells (MSCs) and their derived extracellular vesicles (EVs), in the treatment of ARDS.
methodsA comprehensive literature search of the Cochrane Library, PubMed, and Web of Science databases and the US National Institutes of Health Trials Registry (ClinicalTrials.gov) was conducted to identify eligible studies assessing the efficacy and safety of stem cell-based therapies in ARDS. The primary outcomes included all-cause mortality within or over one month, adverse events (AEs), and serious adverse events (SAEs). To explore possible bias, subgroup analysis was performed based on the design of study (randomized controlled trial vs. nonrandomized interventional trial), etiology of ARDS, type of stem cell-based therapy, and times of infusion. Relative risk (RR) and mean difference (MD) were calculated to evaluate efficacy and safety. This study was registered with PROSPERO (CRD42024593740).
resultsA total of 48 studies involving 1,773 patients were eligible, of which 31 studies were included in the meta-analysis. The results revealed a significant reduction in all-cause mortality among patients receiving MSCs or their derived EVs and secretomes compared to those receiving routine therapy (RR = 0.74, 95% CI = 0.63-0.87, p = 0.0003, I²=5%). This effect was only seen in all-cause mortality within one month (RR = 0.74, 95% CI = 0.62-0.89, p = 0.002, I²=0%); furthermore, high dose MSCs (over 1 × 10
conclusionsStem cell-based therapy significantly reduced mortality within one month and was well tolerated in ARDS patients. Given the limited sample size of included studies, the efficacy of stem cell-based therapy in patients with ARDS needs to be validated in further larger and more rigorous randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.